(Q44258556)

1 December 2017

title

Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy (English)

1 reference

1 December 2017

1 reference

T H Terwey

1

1 reference

1 December 2017

G Massenkeil

2

1 reference

1 December 2017

I Tamm

3

1 reference

1 December 2017

P G Hemmati

4

1 reference

1 December 2017

S Neuburger

5

1 reference

1 December 2017

P Martus

6

1 reference

1 December 2017

B Dörken

7

1 reference

1 December 2017

D Hoelzer

8

1 reference

1 December 2017

R Arnold

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

18 August 2008

1 reference

Bone Marrow Transplantation

1 December 2017

published in

1 reference

1 December 2017

volume

42

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

791-798

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.258

1 December 2017

exact match

0 references

cites work

Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

Acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of relapsed or refractory adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Hematopoietic cell transplantation beyond first remission

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.258

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.258

1 reference

1 December 2017

1 reference